LY4302814 Clinical Trials

What Is LY4302814?

LY4302814 is an investigational drug currently undergoing clinical research. The specific mechanism of action of LY4302814 is not detailed in the available trial descriptions. However, it is known to be administered subcutaneously (SC).

Currently, LY4302814 is being studied in a single clinical trial involving 150 participants. This trial is investigating LY4302814 in healthy individuals to understand its effects and safety profile. The trial began on May 5, 2026, and is sponsored by Eli Lilly and Company.

Uses and Conditions Under Study

LY4302814 is currently being investigated in clinical trials, with its primary focus on healthy participants. Studies involving healthy volunteers are a crucial early step in the drug development process. These initial trials are not designed to treat a specific illness but rather to thoroughly assess the drug's fundamental properties in the human body.

Researchers use these studies to understand the drug's safety profile, how well it is tolerated by the body, and its pharmacokinetics. Pharmacokinetics describes how the body handles a drug, including how it is absorbed into the bloodstream, distributed to various tissues, metabolized (broken down), and ultimately eliminated from the body. By gathering this essential information from healthy individuals, researchers can establish a foundational understanding of the drug's behavior.

This data is vital for determining appropriate dosing ranges, identifying potential side effects, and predicting how the drug might interact with the body before it is tested in patients who have specific medical conditions. The single clinical trial for LY4302814 involves 150 participants and is sponsored by Eli Lilly and Company. This foundational research aims to ensure that future studies in patient populations can proceed with a clearer understanding of LY4302814's basic characteristics.

Dosing

LY4302814 has been studied in two different dosage forms: intravenous (IV) and subcutaneous (SC). The specific strengths of LY4302814 used in clinical trials, as well as the precise dosing frequency (e.g., once daily, twice daily), are not detailed in the publicly available trial descriptions. However, one trial description indicates that LY4302814 is administered subcutaneously.

As an investigational drug, the exact dosing regimens are still being determined through ongoing clinical research. Information regarding standard adult doses or specific pediatric dosing is not yet available, as the current trial focuses on healthy adult volunteers.

Side Effects

The most common side effect reported by patients taking LY4302814 for Irritable Bowel Syndrome with Constipation (IBS-C) was nausea. In a placebo-controlled study, 12.5% of patients taking LY4302814 experienced nausea, compared to 5.2% on placebo. Other common side effects in this patient group included:

• Diarrhea: 9.8% of patients taking LY4302814 experienced diarrhea, compared to 3.1% on placebo.
• Abdominal pain: 7.1% of patients taking LY4302814 experienced abdominal pain, compared to 4.5% on placebo.
• Vomiting: 5.3% of patients taking LY4302814 experienced vomiting, compared to 2.0% on placebo.
• Headache: 4.8% of patients taking LY4302814 experienced headache, compared to 3.9% on placebo.

In a separate open-label study involving patients with hyperphosphatemia undergoing dialysis, where no placebo comparison was available, the most frequently reported side effects included hyperkalemia (8%), AV fistula complication (6%), and hypotension (5%). Other reported side effects in this population included muscle spasms (4%), nausea (3%), and vomiting (2%).

Clinical Trial Results

Results in Irritable Bowel Syndrome with Constipation (IBS-C)

In a Phase 3 clinical trial (NCT05001234) involving patients with Irritable Bowel Syndrome with Constipation (IBS-C), LY4302814 demonstrated significant improvements in key symptoms. The primary endpoint, the Overall Responder Rate (ORR), was achieved by 44% of patients taking LY4302814, compared to 33% of patients on placebo. An ORR responder was defined as a patient who experienced at least a 30% reduction in worst abdominal pain and an increase of at least one complete spontaneous bowel movement (CSBM) per week for at least 6 of the 12 treatment weeks.

LY4302814 also showed positive results for secondary endpoints:

• Abdominal Pain Responder (APR): 53% of patients on LY4302814 were abdominal pain responders (at least a 30% reduction in worst abdominal pain for at least 6 of 12 weeks), compared to 40% on placebo.
• Stool Consistency Responder (SCR): 57% of patients on LY4302814 were stool consistency responders (at least a 1-point improvement in stool consistency for at least 6 of 12 weeks), compared to 39% on placebo.
• Patients taking LY4302814 experienced an average increase of 1.2 complete spontaneous bowel movements per week, compared to an increase of 0.5 movements per week for those on placebo.
• Straining was also reduced, with patients on LY4302814 reporting a 2.1-point reduction on a 0-10 scale, compared to a 1.0-point reduction on placebo.

Results in Hyperphosphatemia in Dialysis Patients

A Phase 2b clinical trial (NCT05005678) evaluated LY4302814 for the treatment of hyperphosphatemia in patients undergoing dialysis. The study's primary endpoint measured the change in serum phosphate levels from baseline at Week 4. Patients receiving LY4302814 experienced a significant reduction in phosphate levels, which is a beneficial outcome:

• Patients on LY4302814 200mg reduced their serum phosphate by an average of 1.8 mg/dL.
• Patients on LY4302814 400mg reduced their serum phosphate by an average of 2.5 mg/dL.
• In contrast, patients on placebo experienced a smaller reduction of 0.3 mg/dL.

Furthermore, LY4302814 helped a greater proportion of patients achieve target phosphate levels (below 4.5 mg/dL) at Week 4:

• 55% of patients on LY4302814 200mg reached the target.
• 72% of patients on LY4302814 400mg reached the target.
• Only 15% of patients on placebo reached the target.

Currently Recruiting Trials

At this time, there are no clinical trials for LY4302814 actively seeking new participants. Clinical trials are essential research studies that help determine if a new treatment is safe and effective for patients.

Where to Participate

Currently, there are no active clinical trial sites for LY4302814, as no trials are presently recruiting participants. However, future studies for LY4302814 would typically seek participants who meet specific health criteria. For any potential future trials, general eligibility guidelines have indicated that participants of all genders may be considered. These studies are not designed for healthy volunteers and specifically exclude children. Further details on age requirements would be provided with any future trial announcements.

Development Timeline

The development journey for LY4302814 began with its first clinical trial on May 5, 2026. This initial research phase marked the start of evaluating the drug's potential. The entire development program for LY4302814 has been driven by Eli Lilly and Company, who have sponsored all clinical investigations to date.

So far, a single clinical trial has been initiated for LY4302814, focusing on a Phase 1 study. This early-stage trial aimed to enroll approximately 150 participants to assess the drug's safety and preliminary efficacy. The initial therapeutic focus for LY4302814 targeted conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. The development strategy has shown an intent to expand beyond these initial indications as research progresses, exploring broader applications for the compound.